TLSC is proud to present our members! Read on to learn about Age Labs’ work, which aims to take on age related illness.

“Our ultimate objective is to help delay the onset of all age-related diseases,”  -Espen Riskedal, Age Labs CEO

Age Labs AS is an Oslo-based biomarker discovery company which is developing a epigenetics-based biomarker. This marker will predict all-cause mortality risk and risk of developing certain age-related diseases.

The biomarker will help pharmaceutical companies increase their probability of success in clinical trials by providing more accurate risk information about the patients participating in trials. Age Labs apply machine learning techniques on large epigenetic datasets from Norwegian and international biobanks.

The Research Council of Norway has awarded Age Labs €1 million in R&D funding to support the development of their unique biomarker. Age Labs is already collaborating with Fürst Medical Laboratory, the Norwegian Institute of Public Health, and the University of Oslo among others. 

Age Labs CEO Espen Riskedal says the following on his decision to join TLSC: «TLSC offers an unrivalled access to the Life Science business networks in Oslo and Norway, along with a host of useful and interesting events. We are happy to be on board!»

Read more about Age Labs here: www.agelabs.com

Share This